Short Interest in bioAffinity Technologies, Inc. (NASDAQ:BIAF) Grows By 18.0%

bioAffinity Technologies, Inc. (NASDAQ:BIAF) was the recipient of a significant increase in short interest in September. As of September 30th, there was short interest totalling 396,200 shares, an increase of 18.0% from the September 15th total of 335,900 shares. Currently, 5.3% of the shares of the company are short sold. Based on an average daily volume of 110,000 shares, the days-to-cover ratio is currently 3.6 days.

bioAffinity Technologies Stock Performance

Shares of BIAF traded up $0.16 during mid-day trading on Wednesday, hitting $2.14. 139,553 shares of the company traded hands, compared to its average volume of 132,482. bioAffinity Technologies has a 1 year low of $1.15 and a 1 year high of $3.62. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.14 and a current ratio of 1.15. The stock has a 50-day moving average price of $1.76 and a two-hundred day moving average price of $2.13. The stock has a market cap of $24.95 million, a price-to-earnings ratio of -2.28 and a beta of 2.92.

bioAffinity Technologies (NASDAQ:BIAF) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.19) earnings per share for the quarter. bioAffinity Technologies had a negative net margin of 120.76% and a negative return on equity of 172.06%. The firm had revenue of $2.40 million for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in bioAffinity Technologies stock. Ground Swell Capital LLC acquired a new position in bioAffinity Technologies, Inc. (NASDAQ:BIAF) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 22,864 shares of the company’s stock, valued at approximately $49,000. Ground Swell Capital LLC owned 0.20% of bioAffinity Technologies as of its most recent SEC filing. Hedge funds and other institutional investors own 1.64% of the company’s stock.

Analyst Ratings Changes

Separately, Maxim Group began coverage on bioAffinity Technologies in a research report on Tuesday, July 23rd. They set a “buy” rating and a $6.00 price objective on the stock.

About bioAffinity Technologies

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.